DK0857210T3 - Terapeutiske antiangiogeniske sammensætninger og metoder - Google Patents

Terapeutiske antiangiogeniske sammensætninger og metoder

Info

Publication number
DK0857210T3
DK0857210T3 DK96936842T DK96936842T DK0857210T3 DK 0857210 T3 DK0857210 T3 DK 0857210T3 DK 96936842 T DK96936842 T DK 96936842T DK 96936842 T DK96936842 T DK 96936842T DK 0857210 T3 DK0857210 T3 DK 0857210T3
Authority
DK
Denmark
Prior art keywords
methods
antiangiogenic compositions
therapeutic
therapeutic antiangiogenic
compositions
Prior art date
Application number
DK96936842T
Other languages
English (en)
Inventor
S O'reilly Michael
M Judah Folkman
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/740,168 external-priority patent/US5854205A/en
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of DK0857210T3 publication Critical patent/DK0857210T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
DK96936842T 1995-10-23 1996-10-23 Terapeutiske antiangiogeniske sammensætninger og metoder DK0857210T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US583595P 1995-10-23 1995-10-23
US2307096P 1996-08-02 1996-08-02
US2626396P 1996-09-17 1996-09-17
US08/740,168 US5854205A (en) 1995-10-23 1996-10-22 Therapeutic antiangiogenic compositions and methods
PCT/US1996/016925 WO1997015666A1 (en) 1995-10-23 1996-10-23 Therapeutic antiangiogenic compositions and methods

Publications (1)

Publication Number Publication Date
DK0857210T3 true DK0857210T3 (da) 2004-01-12

Family

ID=27485527

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96936842T DK0857210T3 (da) 1995-10-23 1996-10-23 Terapeutiske antiangiogeniske sammensætninger og metoder

Country Status (16)

Country Link
US (9) US6630448B2 (da)
EP (1) EP0857210B1 (da)
JP (2) JP3840262B2 (da)
KR (1) KR19990066981A (da)
CN (1) CN1202932A (da)
AT (1) ATE248912T1 (da)
AU (1) AU717277B2 (da)
BR (1) BR9611174A (da)
CZ (1) CZ117798A3 (da)
DE (1) DE69629826T2 (da)
DK (1) DK0857210T3 (da)
ES (1) ES2206602T3 (da)
IL (1) IL124153A (da)
NO (1) NO981803L (da)
NZ (1) NZ321356A (da)
WO (1) WO1997015666A1 (da)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
AU2004202593B2 (en) * 1995-10-23 2008-01-03 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
DE19615710A1 (de) * 1996-04-22 1997-10-23 Forssmann Wolf Georg Verfahren zur Gewinnung und Anwendung eines biologisch aktiven Eiweisstoffes - Kollagenfragment HF-COLL-18/514cf - in partiell aufgereinigter und synthetischer Form aus Körperflüssigkeiten zur Beeinflussung des Zellwachstums und der Diagnose von Kollagenerkrankungen sowie der Osteoporose
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
IL132323A0 (en) 1997-04-28 2001-03-19 Rhone Poulenc Rorer Sa Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
WO1999016889A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
ATE319840T1 (de) * 1997-12-08 2006-03-15 Beth Israel Hospital Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
US6852691B1 (en) 1997-12-08 2005-02-08 Beth Israel Deaconess Medical Center Anti-angiogenic peptides and methods of use thereof
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
JP2002502831A (ja) 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
US6121236A (en) 1998-03-24 2000-09-19 The Children's Medical Center Corporation Multivalent ligands which modulate angiogenesis
AU3199999A (en) * 1998-03-24 1999-10-18 Children's Medical Center Corporation Endostatin derived peptides with anti-angiogenic and anti-cancer activity
AU748751B2 (en) * 1998-03-27 2002-06-13 University Of Kansas Medical Center The use of isolated domains of type IV collagen to modify cell and tissue interactions
RU2229305C2 (ru) * 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
AU4414099A (en) * 1998-06-03 1999-12-20 Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of usingthe same
CA2337496A1 (en) * 1998-07-27 2000-02-10 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
EP1107989B1 (en) * 1998-08-25 2010-03-31 Merck Patent GmbH Expression and export of angiostatin and endostatin as immunofusins
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU4342000A (en) * 1999-04-13 2000-11-14 Merck & Co., Inc. Soluble recombinant endostatin and method of making same from (streptomyces sp)
IT1312077B1 (it) 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
US6369021B1 (en) * 1999-05-07 2002-04-09 Ecolab Inc. Detergent composition and method for removing soil
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
SG87828A1 (en) * 1999-09-03 2002-04-16 Univ Singapore Small peptides having potent anti-angiogenic activity
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
AU2002224403A1 (en) * 2000-10-13 2002-04-22 Entremed, Inc Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
CN1455682A (zh) 2001-01-05 2003-11-12 百疗医株式会社 包括编码抗－血管生成蛋白或者其部分的基因的用于类风湿性关节炎的基因治疗的组合物
EP1401480B1 (en) 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
ITMI20010394A1 (it) * 2001-02-27 2002-08-27 Univ Degli Studi Milano Peptidi ad attivita' antiangiogenica
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
PT1383785E (pt) 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
JP2006517917A (ja) * 2002-12-19 2006-08-03 アルザ・コーポレーシヨン 血管新生性の組織増殖の治療方法
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
KR100579660B1 (ko) * 2003-08-18 2006-05-15 정인식 제미니바이러스 발현시스템을 이용한 재조합 신생혈관생성억제 단백질의 제조방법
EP1668129B1 (en) * 2003-08-29 2008-10-29 Children's Medical Center Corporation Anti-angiogenic peptides from the n-terminus of endostatin
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US7662945B2 (en) * 2005-02-01 2010-02-16 Massachusetts Eye & Ear Infirmary Neostatins
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1934867A2 (en) * 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
HUE028179T2 (en) 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
JP4745851B2 (ja) * 2006-02-09 2011-08-10 キヤノン株式会社 撮像装置
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
KR101263424B1 (ko) 2008-04-04 2013-05-14 조대웅 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8218068B2 (en) * 2009-04-01 2012-07-10 Omnivision Technologies, Inc. Exposing pixel groups in producing digital images
WO2011014726A1 (en) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Mtor inhibitor and angiogenesis inhibitor combination therapy
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
US8833064B2 (en) * 2009-11-06 2014-09-16 Basf Corporation Small engine layered catalyst article and method of making
CA2783656A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8828343B2 (en) * 2010-03-05 2014-09-09 Basf Corporation Carbon monoxide conversion catalyst
US8698496B2 (en) * 2010-09-20 2014-04-15 The General Hospital Corporation Method for two-dimensional correlation magnetic resonance spectroscopy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012122334A2 (en) * 2011-03-08 2012-09-13 The Johns Hopkins University Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2561888A1 (en) 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
CN104411332B (zh) 2012-03-30 2018-11-23 索伦托治疗有限公司 与vegfr2结合的全人抗体
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013158617A1 (en) * 2012-04-16 2013-10-24 The Board Of Trustees Of The University Of Illinois Endostatin peptides and use thereof
KR101539700B1 (ko) * 2012-09-05 2015-07-28 아주대학교산학협력단 연골세포 유래 세포외 기질막을 이용한 신생혈관질환 치료용 조성물 및 각막 또는 결막 이식재
EP3126521B1 (en) 2014-04-04 2019-03-20 Crown Bioscience, Inc. (Taicang) Hnf4g-rspo2 fusion gene
JP6903633B2 (ja) * 2015-07-27 2021-07-14 上海吉貝医薬科技有限公司Ｇ−Ｂｉｏ Ｐｈａｒｍａ Ｔｅｃｈ Ｃｏ．， Ｌｔｄ． 腫瘍抑制ペプチド
CN108601752A (zh) 2015-12-03 2018-09-28 安吉奥斯医药品有限公司 用于治疗mtap缺失型癌症的mat2a抑制剂
CN110191721A (zh) 2016-09-26 2019-08-30 集合集团控股公司 有淋巴系统失调的受试者中癌症的评估与治疗方法
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836391A (ja) 1981-08-07 1983-03-03 Sankyo Co Ltd 新生理活性物質アンジオスタチン
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
US4889806A (en) * 1987-04-15 1989-12-26 Washington University Large DNA cloning system based on yeast artificial chromosomes
US5302390A (en) * 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
WO1993016716A1 (en) * 1992-02-24 1993-09-02 Northwestern University Method and composition for inhibiting angiogenesis
HUT64977A (en) 1992-07-30 1994-03-28 Yeda Res & Dev Synthetical peptone derivatives of vitronectine and pharmaceutical preparaties containing them
US5643783A (en) * 1993-12-01 1997-07-01 President And Fellows Of Harvard College Collagen and uses therefor
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
HUT76095A (en) * 1994-04-26 1997-06-30 Childrens Medical Center Angiostatin and method of use for inhibition of angiogenesis
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
AU3724495A (en) 1994-09-13 1996-03-29 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
CN1060521C (zh) 1997-09-10 2001-01-10 徐根兴 一种人实体肿瘤血管内皮细胞增殖抑制因子的基因克隆方法及在抗肿瘤血管再生治疗中的应用

Also Published As

Publication number Publication date
US6544758B2 (en) 2003-04-08
KR19990066981A (ko) 1999-08-16
US20040102372A1 (en) 2004-05-27
CN1202932A (zh) 1998-12-23
NZ321356A (en) 1998-11-25
US6764995B2 (en) 2004-07-20
AU717277B2 (en) 2000-03-23
US7101979B1 (en) 2006-09-05
JP2002501362A (ja) 2002-01-15
US20030219426A1 (en) 2003-11-27
AU7466696A (en) 1997-05-15
CZ117798A3 (cs) 1998-08-12
US20020127595A1 (en) 2002-09-12
EP0857210A1 (en) 1998-08-12
WO1997015666A1 (en) 1997-05-01
ES2206602T3 (es) 2004-05-16
IL124153A (en) 2008-03-20
DE69629826T2 (de) 2004-07-01
NO981803L (no) 1998-06-17
BR9611174A (pt) 1999-09-14
US7179608B2 (en) 2007-02-20
US20020086352A1 (en) 2002-07-04
ATE248912T1 (de) 2003-09-15
DE69629826D1 (de) 2003-10-09
NO981803D0 (no) 1998-04-22
US20030087393A1 (en) 2003-05-08
JP2004236662A (ja) 2004-08-26
EP0857210B1 (en) 2003-09-03
US20020155987A1 (en) 2002-10-24
JP3840262B2 (ja) 2006-11-01
US7655458B2 (en) 2010-02-02
US6630448B2 (en) 2003-10-07
US20020123458A1 (en) 2002-09-05
US6746865B1 (en) 2004-06-08

Similar Documents

Publication Publication Date Title
DK0857210T3 (da) Terapeutiske antiangiogeniske sammensætninger og metoder
NO974943D0 (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
ATE181913T1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)- benzopyran für die behandlung von proliferativer erkrankungen
ATE259420T1 (de) Mutanten des keratinocyten-wachstumsfaktor-2 (kgf-2 oder fibroblastenwachstumsfaktor-12,fgf-12)
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
PT991619E (pt) Inibidores da adesao celular mediada pela alfa4beta1
ES2172579T3 (es) Agonistas/antagonistas de estrogenos.
DE69807349D1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
ATE241354T1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
NO934218D0 (no) Inhibitorer av cathepsin G og elastase for forhindring avbindevevsnedbrytning
ATE228004T1 (de) Verwendung von relaxin zur stimulierung der angiogenese
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
ATE198477T1 (de) Benzothiophenderivate
BR9917495A (pt) Derivados o ácido betulìnico tendo atividade antiangiogênica, processos para produzir tais derivados e sua utilização para o tratamento de antiogênese associada a tumores
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
ID26524A (id) Turunan-turunan kroman tersubstitusi karboksil bermanfaat sebagai agonis beta-3 adrenoreseptor
ATE309352T1 (de) Inhibitoren der nf-kb aktivierung
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ZA9610073B (en) Method of using beta-interferons to treat restenosis
TR200003084T2 (tr) Paroxetine askorbat
DE69715898D1 (de) Verwendung von hyaluronidase
ES320939A1 (es) Un procedimiento de sintesis de metilamidas de los acidos 3fenil-3-(4-piridil)-3-hidroxipropionico y 3-fenil-3- (2-piridil)-3-hidroxipropionico.
ITMI911597A0 (it) Composizione di trattamento di acque di rifiuto da destinare al riciclo, e procedimento di riciclo di acque di rifiuto che utilizza questa composizione